>ヨーロッパの運動失調症市場、タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療と診断)、剤形別(固形、液体、その他)、投与経路別(経口、非経口、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他) - 2029年までの業界動向と予測。
ヨーロッパ市場の分析と洞察
運動失調症の罹患率の増加により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に貢献しています。この重要な時期に、主要な市場プレーヤーは製品の発売と承認に非常に注力しています。さらに、政府と規制当局は、急増する新興疾患に対する製品承認によって市場プレーヤーをサポートしています。
ヨーロッパの運動失調症市場は、市場プレーヤーの増加と高度な製品の利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場に新製品を投入するための研究開発活動に取り組んでいます。運動失調症治療の分野での研究の増加と、アルコール消費と薬物使用の増加により、市場の成長がさらに促進されると予想されます。ただし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設が不足しているため、予測期間中のヨーロッパの運動失調症市場の成長が妨げられる可能性があります。
医療費の増加と市場プレーヤーによる戦略的取り組みにより、市場には治療を強化する機会がもたらされる可能性があります。ただし、医薬品や製品の承認に関連する厳格な規則や規制、さまざまな企業による製品リコールが、市場の成長を妨げると予想されます。
ヨーロッパの運動失調症市場は、2022年から2029年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に5.8%のCAGRで成長し、2021年の7,424.22千米ドルから2029年には11,169.71千米ドルに達すると分析しています。
レポートメトリック |
詳細 |
予測期間 |
2022年から2029年 |
基準年 |
2021 |
歴史的な年 |
2020 |
定量単位 |
収益は1000米ドル、価格は米ドル |
対象セグメント |
タイプ別(脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA)))、製品別(治療および診断)、剤形別(固形剤、液体剤、その他)、投与経路別(経口剤、非経口剤、その他)、患者タイプ別(成人、小児、高齢者)、エンドユーザー別(病院、診療所、在宅医療、その他)、流通チャネル別(直接入札、小売販売、その他) |
対象国 |
ドイツ、フランス、イギリス、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他のヨーロッパ諸国 |
対象となる市場プレーヤー |
Novartis AG、Merck KGaA、Aurobindo Pharma、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Acorda Therapeutics、Inc.、Viatris Inc.、Sun Pharmaceutical Industries Ltd.、Lupin、Amneal Pharmaceuticals LLC、Cipla Inc.、Intrabio、Biohaven Pharmaceuticals、Priory、その他 |
市場の定義
運動失調症は、協調運動、バランス、発話に影響を及ぼす一連の障害を指す用語です。どの部位にも影響が出る可能性がありますが、運動失調症の人はバランス、歩行、発話、嚥下、および書くこと、食べること、視覚など高度な制御を必要とする作業に困難を抱えることがよくあります。正確な症状とその重症度は、患者の運動失調症の種類によって異なります。
運動失調症は通常、脳の小脳と呼ばれる部分の損傷によって起こりますが、神経系の他の部分の損傷によっても起こることがあります。この損傷は、MS (多発性硬化症) などの基礎疾患の一部である場合もあれば、頭部外傷、脳への酸素不足、長期にわたる過度のアルコール摂取によって起こる場合もあります。遺伝性運動失調症は、影響を受けるかどうかは不明ですが、家族から受け継がれた欠陥遺伝子によって引き起こされます。
ヨーロッパの運動失調症市場の動向
ドライバー
- 運動失調症の有病率と発症率の増加
運動失調症は、運動と協調性に影響を与える神経系に関連する神経疾患のグループを指す用語です。運動失調症の人は、バランス、協調性、嚥下、発話に問題を抱えることがよくあります。運動失調症は通常、運動を調整する小脳である脳の一部が損傷することで発症します。これはまれな病気ですが、その発症は世界中で非常に多く見られます。この病気は世界中で大きな臨床問題として広く認識されており、罹患率と死亡率の負担が大きくなっています。そのため、さまざまな年齢層に影響を与える運動失調症の罹患率と発症率の増加が、ヨーロッパの運動失調症市場を牽引しています。
- 自己免疫疾患の発症数の増加
多発性硬化症などの自己免疫疾患も、持続性運動失調症の原因の 1 つです。多発性硬化症 (MS) は、脳と脊髄 (中枢神経系) に障害を引き起こす可能性のある疾患です。MS では、免疫系が神経線維を覆う保護鞘 (ミエリン) を攻撃し、脳と体の他の部分との間のコミュニケーションに問題を引き起こします。運動失調症を引き起こすこのような自己免疫疾患は、この地域で増加しています。
機会
- 医療費の増大
各国の人々の可処分所得が増加しているため、医療費は世界中で増加しています。さらに、人口の要件を満たすために、政府機関と医療機関は医療費の加速化に積極的に取り組んでいます。医療費の増加は同時に、近年この疾患が蔓延しているため、医療現場が運動失調症の治療設備を改善するのにも役立っています。
また、主要な市場プレーヤーが講じる戦略的取り組みは、2022~2029年の予測期間において、ヨーロッパの運動失調症市場に構造的完全性と将来の機会をもたらすでしょう。
制約/課題
しかし、一部の発展途上国では病気の診断が難しく、遺伝子検査施設も不足しているため、ヨーロッパの運動失調症市場の成長率は低下するでしょう。さらに、厳しい規則や規制が予測期間の市場にさらなる課題をもたらすでしょう。
このヨーロッパの運動失調症市場レポートでは、最近の新しい開発、貿易規制、輸出入分析、生産分析、バリュー チェーンの最適化、市場シェア、国内および現地の市場プレーヤーの影響、新たな収益源の観点から見た機会の分析、市場規制の変更、戦略的市場成長分析、市場規模、カテゴリ市場の成長、アプリケーションのニッチと優位性、製品の承認、製品の発売、地理的拡大、市場における技術革新などの詳細が提供されます。ヨーロッパの運動失調症市場に関する詳細情報を取得するには、アナリスト ブリーフについて Data Bridge Market Research にお問い合わせください。当社のチームが、市場の成長を達成するための情報に基づいた市場決定を行うお手伝いをいたします。
COVID-19後の欧州運動失調症市場への影響
COVID-19は市場にプラスの影響を与えています。パンデミック中のロックダウンと隔離は、病気の管理と服薬遵守を複雑にします。そのため、さまざまな治療薬が世界中の人口に広く増加しています。したがって、パンデミックはこの市場にプラスの影響を与えています。
最近の開発
- 2017年1月、オーロビンドファーマはポルトガルのジェネリスファーマセウティカSA社を買収したことを発表しました。この会社はポルトガルの大手医薬品メーカーです。この買収により、同社は世界的なプレゼンスを高めることができました。
ヨーロッパの運動失調症市場の範囲
ヨーロッパの運動失調症市場は、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネルに区分されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
タイプ
- 脊髄小脳失調症
- 毛細血管拡張性運動失調症
- 発作性運動失調症
- その他(多系統萎縮症(MSA))
タイプに基づいて、ヨーロッパの運動失調症市場は、脊髄小脳失調症、毛細血管拡張性運動失調症、発作性運動失調症、その他(多系統萎縮症(MSA))に分類されます。
製品
- 診断
- 処理
製品に基づいて、ヨーロッパの運動失調症市場は治療と診断に分類されます。
剤形
- 固体
- 液体
- その他
剤形に基づいて、ヨーロッパの運動失調症市場は、固体、液体、その他に分類されます。
投与経路
- オーラル
- 非経口
- その他
投与経路に基づいて、ヨーロッパの運動失調症市場は経口、非経口、その他に分類されます。
患者タイプ
- アダルト
- 子供
- 老年病
患者タイプに基づいて、ヨーロッパの運動失調症市場は、成人、小児、高齢者に分類されます。
エンドユーザー
- 病院
- クリニック
- 在宅医療
- その他
エンドユーザーに基づいて、ヨーロッパの運動失調症市場は、病院、診療所、在宅医療、その他に分類されます。
流通チャネル
- 直接入札
- 小売販売
- その他
流通チャネルに基づいて、ヨーロッパの運動失調症市場は、直接入札、小売販売、その他に分類されます。
ヨーロッパの運動失調症市場の地域分析/洞察
ヨーロッパの運動失調症市場が分析され、市場規模の洞察と傾向が国、タイプ、製品、剤形、投与経路、患者タイプ、エンドユーザー、流通チャネル別に提供されます。
この地域に含まれる国には、ドイツ、フランス、イギリス、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他のヨーロッパ諸国などがあります。ドイツは、市場シェアと収益の面でヨーロッパの運動失調症市場を支配すると予想されており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域での運動失調症の有病率が高く、アルコールの使用量が多いためです。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、ヨーロッパ ブランドの存在と可用性、地元および国内ブランドとの激しい競争により直面する課題、販売チャネルの影響が考慮されています。
競争環境とヨーロッパの運動失調症市場シェア分析
ヨーロッパの運動失調症市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、ヨーロッパの運動失調症市場における会社の焦点にのみ関連しています。
ヨーロッパの運動失調症市場で活動している主要企業としては、Novartis AG、Merck KGaA、Aurobindo Pharma、Pfizer Inc.、Sanofi、Teva Pharmaceutical Industries Ltd.、Acorda Therapeutics, Inc.、Viatris Inc.、Sun Pharmaceutical Industries Ltd.、Lupin.、Amneal Pharmaceuticals LLC.、Cipla Inc.、Intrabio、Biohaven Pharmaceuticals、Priory などが挙げられます。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、ヨーロッパと地域、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE ATAXIA MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
6 EUROPE ATAXIA MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCES OF ATAXIA
7.1.2 RAPID RESEARCH IN FIELD OF ATAXIA THERAPEUTICS
7.1.3 RISE IN ALCOHOL AND DRUG USAGE
7.1.4 GROWING NUMBER OF INCIDENCES OF AUTO-IMMUNE DISEASE
7.2 RESTRAINTS
7.2.1 DIFFICULTY IN DIAGNOSIS OF DISEASE
7.2.2 LACK OF GENETIC TESTING IN DEVELOPING COUNTRIES
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE EXPENDITURE
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 STRINGENT RULES AND REGULATIONS
7.4.2 PRODUCT RECALL
8 EUROPE ATAXIA MARKET, BY TYPE
8.1 OVERVIEW
8.2 SPINOCEREBELLAR ATAXIAS
8.2.1 TYPE 3
8.2.2 TYPE 2
8.2.3 TYPE 1
8.2.4 OTHERS
8.3 ATAXIA-TELANGIECTASIA
8.4 EPISODIC ATAXIA
8.5 OTHERS (MULTIPLE SYSTEM ATROPHY (MSA))
9 EUROPE ATAXIA MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 PHARMACOTHERAPY
9.2.1.1 STIFFNESS/SPASTICITY
9.2.1.1.1 GABAPENTIN
9.2.1.1.2 LEVODOPA
9.2.1.1.3 OTHERS
9.2.1.2 GAIT AND TREMORS
9.2.1.2.1 VARENICLINE
9.2.1.2.2 RILUZOLE
9.2.1.2.3 AMANTADINE
9.2.1.2.4 OTHERS
9.2.1.3 ANTI-OXIDANTS
9.2.1.3.1 N‐ACETYLCYSTEINE
9.2.1.3.2 SELEGILINE
9.2.1.3.3 DEHYDROEPIANDROSTERONE
9.2.1.3.4 VITAMIN E
9.2.1.4 NON ANTI-OXIDANTS
9.2.1.4.1 ERYTHROPOIETIN
9.2.1.4.2 DEFERIPRONE
9.2.1.4.3 RESVERATROL
9.2.1.4.4 HISTONE DEACETYLASE INHIBITORS
9.2.1.5 ANTI-ARRHYTHMIC AGENTS
9.2.1.5.1 AMIODARONE
9.2.1.5.2 PROPAFENONE
9.2.1.5.3 FLECAINIDE
9.2.1.5.4 IBUTILIDE
9.2.1.6 ANTI-CARDIAC FAILURE
9.2.1.6.1 BENAZEPRIL
9.2.1.6.2 LISINOPRIL
9.2.1.6.3 CAPTOPRIL
9.2.1.6.4 ENALAPRIL
9.2.1.6.5 FOSINOPRIL
9.2.1.6.6 MOEXIPRIL
9.2.1.6.7 OTHERS
9.2.1.7 ORAL HYPOGLYCEMIC THERAPEUTICS
9.2.1.7.1 BIGUANIDES (METFORMIN)
9.2.1.7.2 SULFONYLUREAS
9.2.1.7.2.1 GLIPIZIDE
9.2.1.7.2.2 GLIMEPIRIDE
9.2.1.7.2.3 GLYBURIDE
9.2.1.7.2.4 OTHERS
9.2.1.7.3 THIAZOLIDINEDIONES
9.2.1.7.4 MEGLITINIDES
9.2.2 LIFESTYLE THERAPY
9.2.2.1 PHYSICAL THERAPY
9.2.2.2 SPEECH THERAPY
9.2.2.3 PALLIATIVE CARE
9.2.2.4 OTHERS
9.2.3 SUPPORTIVE DEVICES
9.2.3.1 WALKING AIDS
9.2.3.2 WHEELCHAIRS
9.2.3.3 OTHERS
9.3 DIAGNOSTICS
9.3.1 IMAGING TEST
9.3.1.1 MRI SCAN
9.3.1.2 OTHERS
9.3.2 BLOOD TEST
9.3.3 GENETIC TESTING
10 EUROPE ATAXIA MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 SOLID
10.2.1 TABLETS
10.2.2 CAPSULES
10.2.3 OTHERS
10.3 LIQUIDS
10.3.1 INJECTION
10.3.2 SOLUTIONS
10.3.3 OTHERS
10.4 OTHERS
11 EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.4 OTHERS
12 EUROPE ATAXIA MARKET, BY PATIENT TYPE
12.1 OVERVIEW
12.2 ADULT
12.2.1 MALE
12.2.2 FEMALE
12.3 CHILD
12.4 GERIATRIC
13 EUROPE ATAXIA MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 HOSPITAL PHARMACY
14.3.2 RETAIL SHOP
14.3.3 ONLINE PHARMACY
14.4 OTHERS
15 EUROPE ATAXIA MARKET, BY GEOGRAPHY
15.1 EUROPE
15.1.1 GERMANY
15.1.2 U.K.
15.1.3 FRANCE
15.1.4 ITALY
15.1.5 SPAIN
15.1.6 SWITZERLAND
15.1.7 NETHERLANDS
15.1.8 IRELAND
15.1.9 RUSSIA
15.1.10 HUNGARY
15.1.11 AUSTRIA
15.1.12 NORWAY
15.1.13 POLAND
15.1.14 TURKEY
15.1.15 LITHUANIA
15.1.16 REST OF EUROPE
16 EUROPE ATAXIA MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 SELECT MEDICAL CORPORATION
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 PFIZER INC.
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 NOVARTIS AG
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 AMNEAL PHARMACEUTICALS LLC.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLI
18.4.5 RECENT DEVELOPMENT
18.5 UPSTREAM REHABILITATION INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 PRIORY
18.6.1 COMPANY SNAPSHOT
18.6.2 COMPANY SHARE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.7 ACORDA THERAPEUTICS, INC.
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 ADVERUM BIOTECHNOLOGIES, INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 APOTEX INC.
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 ATI PHYSICAL THERAPY
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 AUROBINDO PHARMA
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.12 BANNER HEALTH
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 BIOHAVEN PHARMACEUTICALS
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 BIOVISTA
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 CIPLA INC.
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENT
18.16 DESIGN THERAPEUTICS, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENT
18.17 INTRABIO
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
18.18 LUPIN.
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENTS
18.19 MATRIX BIOMED
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 MERCK KGAA
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENTS
18.21 REATA PHARMACEUTICALS, INC.
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENT
18.22 RETROTOPE INC.
18.22.1 COMPANY SNAPSHOT
18.22.2 PRODUCT PORTFOLIO
18.22.3 RECENT DEVELOPMENT
18.23 SANOFI
18.23.1 COMPANY SNAPSHOT
18.23.2 REVENUE ANALYSIS
18.23.3 PRODUCT PORTFOLIO
18.23.4 RECENT DEVELOPMENT
18.24 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.24.1 COMPANY SNAPSHOT
18.24.2 REVENUE ANALYSIS
18.24.3 PRODUCT PORTFOLIO
18.24.4 RECENT DEVELOPMENT
18.25 SUTTER HEALTH
18.25.1 COMPANY SNAPSHOT
18.25.2 PRODUCT PORTFOLIO
18.25.3 RECENT DEVELOPMENTS
18.26 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.26.1 COMPANY SNAPSHOT
18.26.2 REVENUE ANALYSIS
18.26.3 PRODUCT PORTFOLIO
18.26.4 RECENT DEVELOPMENT
18.27 VIATRIS INC.
18.27.1 COMPANY SNAPSHOT
18.27.2 REVENUE ANALYSIS
18.27.3 PRODUCT PORTFOLIO
18.27.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
表のリスト
TABLE 1 EUROPE ATAXIA MARKET: PIPELINE ANALYSIS
TABLE 2 EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 5 EUROPE ATAXIA-TELANGIECTASIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 EUROPE EPISODIC ATAXIA IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 EUROPE OTHERS (MULTIPLE SYSTEM ATROPHY (MSA)) IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 8 EUROPE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 9 EUROPE TREATMENT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 10 EUROPE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 11 EUROPE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 12 EUROPE STIFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 13 EUROPE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 14 EUROPE ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 15 EUROPE NON ANTI- OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 16 EUROPE ANTI- ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 17 EUROPE ANTI- CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 18 EUROPE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 19 EUROPE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 20 EUROPE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 21 EUROPE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 22 EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 24 EUROPE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 25 EUROPE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 26 EUROPE SOLID IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 27 EUROPE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 28 EUROPE LIQUIDS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 EUROPE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 30 EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 32 EUROPE ORAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 EUROPE PARENTERAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 34 EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 EUROPE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 36 EUROPE ADULT IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 EUROPE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 38 EUROPE CHILD IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 EUROPE GERIATRIC IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 EUROPE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 EUROPE HOSPITAL IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 EUROPE CLINICS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 43 EUROPE HOME HEALTHCARE IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 44 EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 46 EUROPE DIRECT TENDER IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 47 EUROPE RETAIL SALES IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 EUROPE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 49 EUROPE OTHERS IN ATAXIA MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 50 EUROPE ATAXIA MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 51 EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 52 EUROPE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 53 EUROPE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 54 EUROPE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 55 EUROPE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 56 EUROPE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 57 EUROPE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 58 EUROPE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 59 EUROPE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 60 EUROPE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 61 EUROPE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 62 EUROPE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 63 EUROPE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 64 EUROPE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 65 EUROPE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 66 EUROPE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 67 EUROPE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 68 EUROPE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 69 EUROPE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 70 EUROPE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 71 EUROPE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 72 EUROPE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 73 EUROPE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 74 EUROPE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 75 EUROPE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 76 EUROPE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 77 GERMANY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 GERMANY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 79 GERMANY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 80 GERMANY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 81 GERMANY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 82 GERMANY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 83 GERMANY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 84 GERMANY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 85 GERMANY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 86 GERMANY ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 87 GERMANY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 88 GERMANY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 89 GERMANY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 90 GERMANY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 91 GERMANY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 92 GERMANY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 93 GERMANY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 94 GERMANY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 95 GERMANY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 96 GERMANY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 97 GERMANY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 98 GERMANY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 99 GERMANY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 100 GERMANY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 GERMANY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 GERMANY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 U.K. ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 U.K. SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 105 U.K. ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 106 U.K. TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 107 U.K. PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 108 U.K. STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 109 U.K. GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 110 U.K. ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 111 U.K. NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 112 U.K. ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 113 U.K. ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 114 U.K. ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 115 U.K. SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 116 U.K. LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 117 U.K. SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 118 U.K. DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 119 U.K. IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 120 U.K. ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 121 U.K. SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 122 U.K. LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 123 U.K. ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 124 U.K. ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 125 U.K. ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 126 U.K. ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 127 U.K. ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 128 U.K. RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 129 FRANCE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 130 FRANCE SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 131 FRANCE ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 132 FRANCE TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 133 FRANCE PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 134 FRANCE STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 135 FRANCE GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 136 FRANCE ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 137 FRANCE NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 138 FRANCE ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 139 FRANCE ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 140 FRANCE ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 141 FRANCE SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 142 FRANCE LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 143 FRANCE SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 144 FRANCE DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 145 FRANCE IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 146 FRANCE ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 147 FRANCE SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 148 FRANCE LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 149 FRANCE ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 150 FRANCE ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 151 FRANCE ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 152 FRANCE ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 153 FRANCE ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 154 FRANCE RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 155 ITALY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 156 ITALY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 157 ITALY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 158 ITALY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 159 ITALY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 160 ITALY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 161 ITALY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 162 ITALY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 163 ITALY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 164 ITALY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 165 ITALY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 166 ITALY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 167 ITALY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 168 ITALY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 169 ITALY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 170 ITALY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 171 ITALY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 172 ITALY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 173 ITALY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 174 ITALY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 175 ITALY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 176 ITALY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 177 ITALY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 178 ITALY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 179 ITALY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 180 ITALY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 181 SPAIN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 182 SPAIN SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 183 SPAIN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 184 SPAIN TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 185 SPAIN PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 186 SPAIN STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 187 SPAIN GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 188 SPAIN ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 189 SPAIN NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 190 SPAIN ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 191 SPAIN ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 192 SPAIN ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 193 SPAIN SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 194 SPAIN LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 195 SPAIN SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 196 SPAIN DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 197 SPAIN IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 198 SPAIN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 199 SPAIN SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 200 SPAIN LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 201 SPAIN ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 202 SPAIN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 203 SPAIN ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 204 SPAIN ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 205 SPAIN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 206 SPAIN RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 207 SWITZERLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 208 SWITZERLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 209 SWITZERLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 210 SWITZERLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 211 SWITZERLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 212 SWITZERLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 213 SWITZERLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 214 SWITZERLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 215 SWITZERLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 216 SWITZERLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 217 SWITZERLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 218 SWITZERLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 219 SWITZERLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 220 SWITZERLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 221 SWITZERLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 222 SWITZERLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 223 SWITZERLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 224 SWITZERLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 225 SWITZERLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 226 SWITZERLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 227 SWITZERLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 228 SWITZERLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 229 SWITZERLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 230 SWITZERLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 231 SWITZERLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 232 SWITZERLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 233 NETHERLANDS ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 234 NETHERLANDS SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 235 NETHERLANDS ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 236 NETHERLANDS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 237 NETHERLANDS PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 238 NETHERLANDS STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 239 NETHERLANDS GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 240 NETHERLANDS ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 241 NETHERLANDS NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 242 NETHERLANDS ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 243 NETHERLANDS ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 244 NETHERLANDS ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 245 NETHERLANDS SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 246 NETHERLANDS LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 247 NETHERLANDS SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 248 NETHERLANDS DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 249 NETHERLANDS IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 250 NETHERLANDS ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 251 NETHERLANDS SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 252 NETHERLANDS LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 253 NETHERLANDS ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 254 NETHERLANDS ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 255 NETHERLANDS ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 256 NETHERLANDS ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 257 NETHERLANDS ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 258 NETHERLANDS RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 259 IRELAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 260 IRELAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 261 IRELAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 262 IRELAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 263 IRELAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 264 IRELAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 265 IRELAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 266 IRELAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 267 IRELAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 268 IRELAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 269 IRELAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 270 IRELAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 271 IRELAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 272 IRELAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 273 IRELAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 274 IRELAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 275 IRELAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 276 IRELAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 277 IRELAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 278 IRELAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 279 IRELAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 280 IRELAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 281 IRELAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 282 IRELAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 283 IRELAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 284 IRELAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 285 RUSSIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 286 RUSSIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 287 RUSSIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 288 RUSSIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 289 RUSSIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 290 RUSSIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 291 RUSSIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 292 RUSSIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 293 RUSSIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 294 RUSSIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 295 RUSSIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 296 RUSSIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 297 RUSSIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 298 RUSSIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 299 RUSSIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 300 RUSSIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 301 RUSSIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 302 RUSSIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 303 RUSSIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 304 RUSSIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 305 RUSSIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 306 RUSSIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 307 RUSSIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 308 RUSSIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 309 RUSSIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 310 RUSSIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 311 HUNGARY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 312 HUNGARY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 313 HUNGARY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 314 HUNGARY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 315 HUNGARY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 316 HUNGARY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 317 HUNGARY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 318 HUNGARY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 319 HUNGARY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 320 HUNGARY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 321 HUNGARY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 322 HUNGARY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 323 HUNGARY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 324 HUNGARY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 325 HUNGARY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 326 HUNGARY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 327 HUNGARY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 328 HUNGARY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 329 HUNGARY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 330 HUNGARY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 331 HUNGARY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 332 HUNGARY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 333 HUNGARY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 334 HUNGARY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 335 HUNGARY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 336 HUNGARY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 337 AUSTRIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 338 AUSTRIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 339 AUSTRIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 340 AUSTRIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 341 AUSTRIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 342 AUSTRIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 343 AUSTRIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 344 AUSTRIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 345 AUSTRIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 346 AUSTRIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 347 AUSTRIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 348 AUSTRIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 349 AUSTRIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 350 AUSTRIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 351 AUSTRIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 352 AUSTRIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 353 AUSTRIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 354 AUSTRIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 355 AUSTRIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 356 AUSTRIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 357 AUSTRIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 358 AUSTRIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 359 AUSTRIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 360 AUSTRIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 361 AUSTRIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 362 AUSTRIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 363 NORWAY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 364 NORWAY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 365 NORWAY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 366 NORWAY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 367 NORWAY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 368 NORWAY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 369 NORWAY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 370 NORWAY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 371 NORWAY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 372 NORWAY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 373 NORWAY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 374 NORWAY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 375 NORWAY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 376 NORWAY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 377 NORWAY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 378 NORWAY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 379 NORWAY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 380 NORWAY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 381 NORWAY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 382 NORWAY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 383 NORWAY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 384 NORWAY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 385 NORWAY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 386 NORWAY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 387 NORWAY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 388 NORWAY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 389 POLAND ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 390 POLAND SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 391 POLAND ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 392 POLAND TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 393 POLAND PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 394 POLAND STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 395 POLAND GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 396 POLAND ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 397 POLAND NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 398 POLAND ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 399 POLAND ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 400 POLAND ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 401 POLAND SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 402 POLAND LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 403 POLAND SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 404 POLAND DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 405 POLAND IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 406 POLAND ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 407 POLAND SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 408 POLAND LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 409 POLAND ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 410 POLAND ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 411 POLAND ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 412 POLAND ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 413 POLAND ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 414 POLAND RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 415 TURKEY ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 416 TURKEY SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 417 TURKEY ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 418 TURKEY TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 419 TURKEY PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 420 TURKEY STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 421 TURKEY GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 422 TURKEY ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 423 TURKEY NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 424 TURKEY ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 425 TURKEY ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 426 TURKEY ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 427 TURKEY SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 428 TURKEY LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 429 TURKEY SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 430 TURKEY DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 431 TURKEY IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 432 TURKEY ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 433 TURKEY SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 434 TURKEY LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 435 TURKEY ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 436 TURKEY ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 437 TURKEY ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 438 TURKEY ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 439 TURKEY ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 440 TURKEY RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 441 LITHUANIA ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 442 LITHUANIA SPINOCEREBELLAR ATAXIAS IN ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 443 LITHUANIA ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 444 LITHUANIA TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 445 LITHUANIA PHARMACOTHERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 446 LITHUANIA STIFFNESS/SPASTICITY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 447 LITHUANIA GAIT AND TREMORS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 448 LITHUANIA ANTI-OXIDANTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 449 LITHUANIA NON ANTI-OXIDANTS TREATMENT IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 450 LITHUANIA ANTI-ARRHYTHMIC AGENTS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 451 LITHUANIA ANTI-CARDIAC FAILURE IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 452 LITHUANIA ORAL HYPOGLYCEMIC THERAPEUTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 453 LITHUANIA SULFONYLUREAS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 454 LITHUANIA LIFESTYLE THERAPY IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 455 LITHUANIA SUPPORTIVE DEVICES IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 456 LITHUANIA DIAGNOSTICS IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 457 LITHUANIA IMAGING TEST IN ATAXIA MARKET, BY PRODUCT, 2020-2029 (USD THOUSAND)
TABLE 458 LITHUANIA ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 459 LITHUANIA SOLID IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 460 LITHUANIA LIQUIDS IN ATAXIA MARKET, BY DOSAGE FORM, 2020-2029 (USD THOUSAND)
TABLE 461 LITHUANIA ATAXIA MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 462 LITHUANIA ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 463 LITHUANIA ADULT IN ATAXIA MARKET, BY PATIENT TYPE, 2020-2029 (USD THOUSAND)
TABLE 464 LITHUANIA ATAXIA MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 465 LITHUANIA ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 466 LITHUANIA RETAILS SALES IN ATAXIA MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 467 REST OF EUROPE ATAXIA MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
図表一覧
FIGURE 1 EUROPE ATAXIA MARKET: SEGMENTATION
FIGURE 2 EUROPE ATAXIA MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE ATAXIA MARKET: DROC ANALYSIS
FIGURE 4 EUROPE ATAXIA MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE ATAXIA MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE ATAXIA MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE ATAXIA MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE ATAXIA MARKET: END USER COVERAGE GRID
FIGURE 9 EUROPE ATAXIA MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE ATAXIA MARKET: SEGMENTATION
FIGURE 11 RAPID RESEARCH IN FIELD OF ATAXIA THEREPEUTICS IS EXPECTED TO DRIVE THE EUROPE ATAXIA MARKET IN THE FORECAST PERIOD
FIGURE 12 SPINOCEREBELLAR ATAXIAS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ATAXIA MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE ATAXIA MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ATAXIA MARKET
FIGURE 15 EUROPE ATAXIA MARKET: BY TYPE, 2021
FIGURE 16 EUROPE ATAXIA MARKET: BY TYPE, 2022-2029 (USD THOUSAND)
FIGURE 17 EUROPE ATAXIA MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 EUROPE ATAXIA MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE ATAXIA MARKET: BY PRODUCT, 2021
FIGURE 20 EUROPE ATAXIA MARKET: BY PRODUCT, 2022-2029 (USD THOUSAND)
FIGURE 21 EUROPE ATAXIA MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 22 EUROPE ATAXIA MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 EUROPE ATAXIA MARKET: BY DOSAGE FORM, 2021
FIGURE 24 EUROPE ATAXIA MARKET: BY DOSAGE FORM, 2022-2029 (USD THOUSAND)
FIGURE 25 EUROPE ATAXIA MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 26 EUROPE ATAXIA MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 28 EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD THOUSAND)
FIGURE 29 EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 30 EUROPE ATAXIA MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 EUROPE ATAXIA MARKET: BY PATIENT TYPE, 2021
FIGURE 32 EUROPE ATAXIA MARKET: BY PATIENT TYPE, 2022-2029 (USD THOUSAND)
FIGURE 33 EUROPE ATAXIA MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 34 EUROPE ATAXIA MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 35 EUROPE ATAXIA MARKET: BY END USER, 2021
FIGURE 36 EUROPE ATAXIA MARKET: BY END USER, 2022-2029 (USD THOUSAND)
FIGURE 37 EUROPE ATAXIA MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 EUROPE ATAXIA MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD THOUSAND)
FIGURE 41 EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 EUROPE ATAXIA MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 EUROPE ATAXIA MARKET: SNAPSHOT (2021)
FIGURE 44 EUROPE ATAXIA MARKET: BY COUNTRY (2021)
FIGURE 45 EUROPE ATAXIA MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 EUROPE ATAXIA MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 EUROPE ATAXIA MARKET: BY TYPE (2022-2029)
FIGURE 48 EUROPE ATAXIA MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。